# BioSerenity

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/bioserenity

- Industry: Medical Devices & Equipment
- Headquarters: Paris, France
- Website: www.bioserenity.com
- Total disclosed funding: $2.2M
- Latest round: Series A (Jul 13, 2016)
- Investors on record: 2

## About

BioSerenity is a neuroscience platform that develops and provides connected medical devices aimed at improving the diagnosis and management of neurological conditions.Founded in 2014, BioSerenity operates as a neuroscience platform specializing in connected medical devices. The company is headquartered in Paris, France. Under the leadership of CEO Vincent Marcel, BioSerenity has successfully completed 3 deals, with its latest funding round being a Series C, which raised EUR 29.50 mn on July 3, 2019, led by Dassault Systemes and including Remark International as a participant. The company has achieved a total amount raised of EUR 29.50 mn and currently holds a valuation of EUR 156.67 mn.BioSerenity is a comprehensive integrated neuroscience platform specializing in the development and provision of connected medical devices designed to enhance the diagnosis and management of neurological conditions. Central to its offerings is the Neuronaute, a modular EEG device compatible with nearly all EEG systems on the market, utilizing a Touchproof Adapter for versatile application. This device allows for real-time EEG monitoring, enabling healthcare providers to place electrodes, record, and upload data from various locations, including medical facilities and patients' homes. The IceCap, a single-use EEG headset, is another flagship product that caters to adult patients, requiring no prior EEG training for setup, thus simplifying the process for medical staff. BioSerenity's solutions are utilized by over 9,000 physicians and encompass a client base that includes hospitals, clinics, and telemedicine services across geographical markets such as the United States, Europe, and China, addressing the needs of patients with neurological disorders, sleep issues, and cardiology-related conditions.BioSerenity's revenue stream is derived primarily from its innovative medical devices and telemedicine services offered on a subscription basis to healthcare providers, hospitals, and clinics. The company engages in business-to-business transactions whereby partner hospitals and clinics utilize BioSerenity's products and services for telemetry interpretations of electrophysiological examinations, such as EEG, ECG, and PSG. Revenue is generated through the deployment of devices like the Neuronaute and IceCap, with hospitals typically integrating these products into their diagnostic workflows. The financial structure may involve contractual agreements for device usage, maintenance, and ongoing software support, ensuring a steady revenue flow from their advanced healthcare solutions. Additionally, BioSerenity has established partnerships with over 200 healthcare facilities, facilitating the provision of remote diagnostic services, which further contributes to its revenue model.In July 2019, BioSerenity, SAS raised EUR 30 million in Series C funding led by new investor Dassault Systemes, with participation from Remark International. This funding will support the development of new products and expansion into new geographic regions, enhancing the company’s capabilities in addressing neurological conditions globally.

## Funding rounds

- Series A, Jul 13, 2016, $2.2M — Idinvest Partners, Kurma Partners

## Investors

- Idinvest Partners (https://capitalatlas.ai/funds/idinvest-partners) — Series A
- Kurma Partners (https://capitalatlas.ai/funds/kurma-partners) — Series A